- Home
- / Xeris Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Xeris Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$3.2
2024-10-29
Market Capitalization
$481.3 M
2024-10-29
Revenue
$20.2 M
FY, 2020
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2018 | FY, 2019 | FY, 2020 |
|---|---|---|---|
| Revenue | 100.0K | 1.6M | 20.2M |
| Cost of goods sold | 42.0K | 1.6M | 9.3M |
| Gross profit | 58.0K | 24.0K | 10.8M |
| Gross profit margin, % | 58.0% | 1.5% | 53.7% |
| General and administrative expense | 21.1M | 63.1M | 73.7M |
| Operating expense total | 61.8M | 123.5M | 94.7M |
| EBIT | (59.3M) | (122.4M) | (83.5M) |
| EBIT margin, % | -59344.0% | -7521.8% | -414.5% |
| Interest income | 1.6M | 2.8M | 3.0M |
| Interest expense | 2.5M | 10.7M | |
| Income tax expense | (458.0K) | (110.0K) | |
| Net Income | (60.1M) | (125.6M) | (91.1M) |